DNLI - Company ID 0001714899
The table below shows Denali Therapeutics Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $205.33M | $174.96M | $127.11M | $218.04M | $293.48M | $507.14M |
| Short-term investments | $662.55M | $657.37M | $907.40M | $1.12B | $571.93M | $962.55M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $900.66M |
| $864.44M |
| $1.06B |
| $1.37B |
| $897.23M |
| $1.50B |
| Property, plant & equipment | $52.40M | $55.24M | $45.59M | $44.09M | $38.87M | $40.85M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.14B | $1.37B | $1.15B | $1.46B | $1.40B | $1.60B |
| Accounts payable | $3.33M | $11.14M | $9.48M | $2.79M | $4.78M | $1.07M |
| Total current liabilities | $98.35M | $102.21M | $77.98M | $363.92M | $378.25M | $71.70M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $131.09M | $144.50M | $122.96M | $417.81M | $441.87M | $453.75M |
| Retained earnings | -$2.05B | -$1.54B | -$1.12B | -$970.99M | -$645.00M | -$354.42M |
| Total equity | $1.01B | $1.23B | $1.03B | $1.04B | $962.29M | $1.15B |